Friday, May 24, 2024
HomeAi in FinanceLantern to Join HCW's 1st AI Drug Discovery Virtual Conf

Lantern to Join HCW’s 1st AI Drug Discovery Virtual Conf

Lantern Pharma to Present at Virtual Conference Hosted by HCW

Lantern Pharma Inc. (NASDAQ: LTRN), a prominent player in AI-driven cancer drug discovery and development, has revealed that it will be participating in a virtual conference organized by HCW. The event is scheduled for Thursday, March 7th, and will be held online.

The CEO and President of Lantern Pharma, Mr. Panna Sharma, will be featured in a fireside chat interview format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference, commencing at 2 pm Eastern / 11 am Pacific. During the discussion, Mr. Sharma will delve into the topic of AI in drug discovery, shedding light on how RADR®, Lantern’s proprietary AI platform, is revolutionizing the landscape of oncology drug development by enhancing efficiency, speed, and accuracy.

Recent announcements by Lantern Pharma have highlighted the significant milestone of RADR® surpassing 60 billion data points, with further expansion to 100 billion data points anticipated in 2024. This achievement underscores the platform’s capabilities in driving innovation within cancer therapy development, enabling more precise, durable, and personalized solutions.

Industry stakeholders, including institutional investors, companies, and professionals, are encouraged to register for the event in advance through the provided link or by contacting their respective HCW representative for additional information.

RADR® stands as Lantern Pharma’s integrated AI platform designed for comprehensive biomarker and drug-tumor interaction data analytics, leveraging advanced machine learning techniques. The platform plays a crucial role in offering insights into drug-tumor interactions, predicting potential response outcomes for various cancer types and subtypes, and identifying patient groups likely to benefit from emerging therapies developed in collaboration with Lantern Pharma and its partners.

Utilizing an ensemble-based approach, RADR® harnesses a diverse array of algorithms for tackling complex statistical and correlative challenges within drug-tumor interactions. Its capacity to process vast quantities of intricate data enables predictions regarding patient and tumor responses to therapeutic combinations, with continuous refinement driven by the integration of new datasets.

The machine-learning methods utilized by RADR® are scalable and instrumental in guiding drug development initiatives, generating novel biological insights, and enhancing response rates and outcomes in clinical trials. As the platform continues to evolve and amass diverse datasets, it is poised to deliver enhanced results, expedite automation processes, and drive advancements in oncology drug development, ultimately aiming to benefit cancer patients.

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) operates as an AI company at the forefront of revolutionizing the pace, cost, and timeline of oncology drug discovery and development. Through its proprietary AI and machine learning platform, RADR®, which leverages over 60 billion oncology-focused data points and a suite of advanced machine learning algorithms, the company addresses critical challenges within oncology drug development. In collaboration with renowned scientific advisors and partners, Lantern Pharma has achieved significant progress in advancing its pipeline of therapies across eleven cancer indications and an antibody-drug conjugate (ADC) program. Notably, the company’s drug programs have been accelerated from initial AI insights to first-in-human clinical trials within an average timeframe of 2-3 years, at a cost of approximately $1.0-2.0 million per program.

For more information, visit:
Twitter: @lanternpharma
Newsletter: Sign-up here

The press release contains forward-looking statements subject to inherent risks and uncertainties, as detailed in the Risk Factors section of the company’s Annual Report on Form 10-K for the year ended December 31, 2022. Investors are advised to consider these factors when evaluating the statements provided.


Investor Relations

In conclusion, Lantern Pharma’s upcoming participation in the virtual conference hosted by HCW underscores the company’s commitment to leveraging AI and machine learning for advancing oncology drug discovery and development. The event promises to be a significant platform for sharing insights, discussing advancements, and fostering collaborations within the field of cancer therapy innovation.

Leah Sirama
Leah Sirama
Leah Sirama, a lifelong enthusiast of Artificial Intelligence, has been exploring technology and the digital realm since childhood. Known for his creative thinking, he's dedicated to improving AI experiences for all, making him a respected figure in the field. His passion, curiosity, and creativity drive advancements in the AI world.


Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular